BP 1202
Alternative Names: BP-1202Latest Information Update: 05 Jul 2022
At a glance
- Originator BrightPath Biotherapeutics
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunomodulators; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 03 Jun 2022 Pharmacodynamics data from a preclinical study in Cancer presented at the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)
- 01 Jun 2022 Preclinical trials in Cancer in Japan (Parenteral) (BrightPath Biotherapeutics pipeline, June 2022)
- 05 Oct 2021 BP 1202 is available for licensing as of 05 Oct 2021. https://www.brightpathbio.com